News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
Kexing Biopharm enrolls first subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10, marking a significant milestone in innovative drug R&D pipeline -